Bixiye
QP50-19 Pharmacy Benefit Exclusion for Intramuscular Route of Administration Medications
Taariikhda wax ku ool ah ee barnaamijka: Jun 12, 2019
Natiijooyinka Raadinta
Soo bandhiga 1321 - 1330 ee natiijooyinka 4162
Bixiye
QP105-20 Update: EquiClaim to Perform Focused and Limited Hospital Bill Validation (HBV) Services
Taariikhda uu dhaqangalayo barnaamijka: Okt 28, 2020
Bixiye
QP103-20 Commercial Pharmacy Benefit Exclusion for Emtricitabine-Tenofovir Disoproxil Fumarate Tablet 200-300 mg
Taariikhda uu dhaqangalayo barnaamijka: Okt 28, 2020
Bixiye
QP104-20 Update: Cotiviti to Perform Focused and Limited Hospital Bill Validation (HBV) Services
Taariikhda uu dhaqangalayo barnaamijka: Okt 28, 2020
Bixiye
QP99-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Insulin Pump PA with QL
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020
Bixiye
QP96-20 Medical Drug Update for New to Market Inclisiran
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020
Bixiye
QP97-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Hemophilia Factor VIII PA with QL
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020
Bixiye
QP98-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Fintepla® (fenfluramine) PA with QL
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020
Bixiye
QP101-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) Criteria: Dojolvi™ PA
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020
Bixiye
QP100-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Hemophilia Factor IX PA with QL
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020